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Systemic treatment for triple negative breast cancer (TNBC: negative for the expression of estrogen receptor and progesterone
receptor andHER2 amplification) has been limited to chemotherapy options. Neoadjuvant chemotherapy induces tumor shrinkage
and improves the surgical outcomes of patients with locally advanced disease and also identifies those at high risk of disease
relapse despite today’s standard of care. By using pathologic complete response as a surrogate endpoint, novel treatment strategies
can be efficiently assessed. Tissue analysis in the neoadjuvant setting is also an important research tool for the identification
of chemotherapy resistance mechanisms and new therapeutic targets. In this paper, we review data on completed and ongoing
neoadjuvant clinical trials in patients with TNBC and discuss treatment controversies that face clinicians and researchers when
neoadjuvant chemotherapy is employed.
1. Introduction
Neoadjuvant chemotherapy, also known as preoperative or
primary systemic therapy, is an option for patients with
breast cancers who require cytotoxic chemotherapy. It was
initially used for patients with locally advanced inoperable
breast cancers [1]. Subsequently tumor regression induced by
chemotherapy allows a proportion of patientswith large oper-
able cancers who hitherto required a mastectomy to achieve
breast conservation. For example, theNational Surgical Adju-
vant Breast and Bowel Project (NSABP) B-18 clinical trial
randomized a large number of women to receive chemother-
apy either pre- or postoperatively [2]. Although there were
no survival differences, preoperative chemotherapy improved
the rate of breast conservation. In those who are already
candidates for breast conservation, neoadjuvant chemother-
apy may also result in a more desirable cosmetic outcome
by allowing less extensive surgery. In addition, neoadjuvant
treatment provides a critical opportunity to assess the in vivo
responsiveness to chemotherapy and a research platform for
investigations of tissue or imaging predictors of response
and novel therapeutic targets. Neoadjuvant chemotherapy
has therefore increasingly become a preferred strategy for
patients with Stage II or III breast cancers.
Triple negative breast cancer (TNBC) is defined clinically
by the absence of estrogen receptor (ER), progesterone
receptor (PgR), and HER2/neu overexpression and encom-
passes a molecularly diverse group of diseases. As TNBC
lacks a clearly defined therapeutic target, patients receive
chemotherapy for their systemic management. Since chemo-
therapy-resistant TNBCcarries a particularly poor prognosis,
the identification of the mechanism of chemoresistance and
therapeutic advances are critical. There is therefore a partic-
ularly strong rationale for clinical research in this setting.
2. Molecular Classification of TNBC
Breast cancer is subdivided into at least five major intrinsic
subtypes, including luminal A, luminal B, HER2-enriched,
basal-like, and claudin-low breast cancer [3]. The majority of
TNBCs belong to the basal-like breast cancer (BLBC) sub-
type, which is characterized by basal gene signature contain-
ing keratins 5, 6, and 17 and high expression of proliferation-
related genes [4]. TNBC and BLBC do not completely
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Table 1: Genomic and proteomic features of basal-like breast cancer (data from TCGA [7]).
Pathways and analysis Aberrations
TP53 pathway TP53 mut (84%); gain of MDM2 (14%)
PIK3CA/PTEN pathway PIK3CA mut (7%); PTEN mut/loss (35%); INPP4B loss (30%)
RB1 pathway RB1 mut/loss (20%); cyclin E1 amp (9%); high expression of CDKN2A; low expression of RB1
Copy number Most aneuploid; high genomic instability; 1q, 10p gain; 8p, 5q loss; MYC focal gain (40%)
Proteomic analysis by reverse
phase protein array High expression of DNA repair proteins, PTEN and INPP4B loss signature (pAKT)
overlap, and the concordance rate ranges from 70 to 90%
in various studies [5, 6]. The other less commonly defined
subtypes of TNBC include (confusingly) luminal tumors.
The Cancer Genome Atlas (TCGA) analysis along with a
number of other genomic studies [7–12] have demonstrated
that BLBC is characterized by frequent alterations in the TP53
pathway, PIK3CA/PTEN pathway, and RB1 pathway and a
high frequency of aneuploidy, genomic instability, and Myc
amplification (Table 1). Interestingly, the genomic alterations
of BLBC, including BRCA1 inactivation, RB1 loss, cyclin
E1 amplification, high expression of AKT3, MYC amplifica-
tion/high expression, a high frequency of TP53 mutations,
and high pathway activity of the HIF1-a/ARNT, MYC, and
FOXM1 regulatory hubs, resemble those of serous ovarian
carcinoma, indicating potential similarities between the two
cancer types in regards to pathogenesis and therapeutic
opportunities [7]. Incorporation of molecular understanding
to drug development is undoubtedly a major research focus
in breast cancer in the years to come [13].
In an effort to identify TNBC-specific molecular sub-
types, Lehmann et al. analyzed the gene expression profile of
587 TNBC cases [14]. Six subtypes were identified, including
the two basal-like subtypes, BL1 and BL2, which were the
most prevalent and were so named because of their similarity
to the basal-like intrinsic subtype. These tumors have high
expression of genes involved in cell cycle and division and
are highly proliferative as marked by high Ki-67 staining.
These results suggest that chemotherapies that target cell
division and mitosis may be most appropriate in this class.
In a recent retrospective study, BL1 and BL2 subtypes were
associated with a higher rate of pCR (63%; 𝑃 = 0.042) with
third generation, taxane containing regimens, as compared to
mesenchymal-like (31%) or luminal androgen receptor (14%)
subtypes [15]. In addition, elevated expression of DNA dam-
age response pathway genes was present in the BL1 subtype,
and representative cell lines were found to be preferentially
responsive to cisplatin which induces DNA damage through
the formation of predominantly guanine cross-links. A third
subtype, “immunomodulatory,” was found to be enriched in
genes involved in immune processes. These include immune
transduction pathways, cytokine signaling such as IL-2 path-
way, and antigen processing, among others.This subtypemay
represent medullary breast cancer, a subtype of TNBC that
has a relatively good prognosis, based on a similar expression
profile reported in another study [16]. Mesenchymal (M) and
mesenchymal stem-like (MSL) subtypes were characterized
by expression of cell motility genes and proteins of the extra-
cellular matrix.TheMSL subtype displayed low expression of
claudins 3, 4, and 7 and therefore overlaps with the claudin-
low subtype of breast cancer.TheMSL subtype also expressed
genes involved in growth factor signaling such as EGFR and
PDGFR, pointing to possible therapeutic options in this sub-
type. The sixth subtype, luminal androgen receptor (LAR),
was found to be enriched in genes involved in steroid synthe-
sis and androgenmetabolism. It has been reported previously
that a proportion of TNBCmay have a steroid hormone gene
regulation signature despite being negative for ER and PR
[17]. This finding was replicated in the study by Lehmann et
al. Androgen receptor mRNA was expressed at an average
of ninefold higher level in this subtype than all the other
subtypes [18]. Interestingly, LAR subtype is classified to either
luminal A or luminal B intrinsic subtype despite being nega-
tive for ER expression. The finding of LAR subtype presents
a potential venue for endocrine treatment for at least a
proportion of TNBCpatients and clinical trials are underway.
It is likely that the classification of TNBC will continue
to evolve and we envision the development of treatment-
directed classification to also include necessary markers by
either genomic or proteomic analysis. Neoadjuvant setting
provides a platform for proof of concept studies in this regard.
A consensus conference on TNBC definitions, similar to
historic efforts in lymphoma and leukemia, should be con-
sidered to facilitate subset specific clinical trials.
3. Neoadjuvant Chemotherapy for TNBC
While several clinical trials involving traditional chemother-
apy, or biologics have recently been launched in an attempt to
improve the outcome of patients with TNBC, most neoadju-
vant studies have not restricted entry criteria to only patients
with TNBC and so the attempt to define treatment standards
has required retrospective subset analysis, risking underpow-
ered investigation. Nonetheless a large proportion (41%) of
the study population in NSABP protocol B-40 was classified
as having TNBC [19]. The goals of this study were to deter-
mine if the addition of capecitabine or gemcitabine to doc-
etaxel followed by doxorubicin and cyclophosphamide (AC)
would increase pathologic complete response (pCR) rates in
patients with palpable and operable HER2-negative disease
and also to determine whether the addition of bevacizumab
to docetaxel-based regimens followed by AC will increase
pCR rates. In the chemotherapy alone arms, the addition
of capecitabine or gemcitabine to docetaxel versus docetaxel
alone did not increase the pCR rates (29.7% and 31.8%, resp.,
versus 32.7%; 𝑃 = 0.69). Similarly, the GeparTrio study
reported by Huober et al. showed a pCR rate of 39% in
Journal of Oncology 3
Table 2: Summary of completed and ongoing studies of neoadjuvant chemotherapy and targeted therapy in TNBC.
Study 𝑁 Treatment Primary endpoint
Platinum agents
Alba et al. [21] 94 EC
a followed by Db versus EC followed
by D plus Cbc pCR
h
Silver et al. [22] 28 Cisplatin pCR
Sirohi et al. [23] 62 Cisplatin Clinical response rates, OSi
Kern et al. [24] 27 Carboplatin plus docetaxel pCR
Tiley et al. [25] 12 ACd followed by Pe with Cb pCR
GeparSixto [26] Ongoing Carboplatin plus standard chemotherapy pCR
Targeting angiogenesis
Ryan et al. [18] 51 Cisplatin plus bevacizumab Clinical response
CALGB 40603 [26] Ongoing Carboplatin and/or bevacizumab pCR
NCT00887575 [26] Ongoing Sunitinib plus pactlitaxel plus carboplatin MTDj, pCR
NCT01194869 [26] Ongoing Sorafenib plus pactlitaxel plus cisplatin pCR
Targeting DNA damage repair
Llombart et al. [27] 141 Iniparib plus paclitaxel pCR
NCT00813956 [26] Ongoing Gemcitabine plus Cb plus iniparib pCR
I-SPY 2 [26] Ongoing Veliparib plus paclitaxel pCR
Targeting EGFR
ICE [26] Ongoing Ixabepilone plus cetuximab pCR
NCT00491816 [26] Ongoing Erlotinib plus chemotherapy pCR
Targets HER3
NCT01421472 Ongoing Paclitaxel plus MM-121 (targets HER3) pCR
Targets inhibitors of apoptosis (IAP)
NCT01617668 Ongoing Paclitaxel plus LCL161 pCR
Targets gamma-secretase/notch signaling pathway
NCT01238133 Ongoing Paclitaxel plus Cb plus RO4929097 MTD
Targets PI3K/mTOR
Gonzalez-Angulo et al. [28] 62 T-FECf versus TR-FECg Clinical response rate at 12 weeks
NCT00930930 Ongoing Cisplatin plus paclitaxel ± everolimus pCR
Targets multiple tyrosine kinases
NCT00817531 Completed Dasatinib Clinical response by RECIST
aEpirubicin cyclophosphamide, bdocetaxel, ccarboplatin, ddoxorubicin cyclophosphamide, epaclitaxel, fpaclitaxel 5-flourouracil epirubicin cyclophosphamide,
gpaclitaxel everolimus 5-flourouracil epirubicin cyclophosphamide, hpathologic complete response, ioverall survival, jmaximum tolerated dose.
the TNBC patient subset on this trial which sought to deter-
mine the effect on pCR of switching neoadjuvant chemother-
apy depending on mid-course response [20]. Patients
received 2 cycles of docetaxel, doxorubicin, and cyclophos-
phamide (TAC), followed by either 4 or 6 more cycles of TAC
in responders or 4 cycles of TAC versus capecitabine plus
vinorelbine in nonresponders. In nonresponders, pCR rates
were less than 10% in both treatment groups, suggesting
diminished benefits of chemotherapy and lack of benefit for
these particular experiment agents.
As sporadic TNBC has clinical andmolecular similarities
to BRCA-1-associated breast cancers, there has been signifi-
cant interest in using platinum compounds in TNBC. BRCA-
1-associated breast cancers are sensitive to these agents since
double-strand DNA breaks cannot be correctly repaired in
cells deficient in homologous recombination repair mech-
anisms. Several neoadjuvant trials have therefore evaluated
platinum agents in TNBC patients (Table 2). Alba et al.
investigated whether the addition of carboplatin to standard
chemotherapy in patient with TNBC would lead to an
increase in the pCR rates in the neoadjuvant setting [21].
Patients received epirubicin plus cyclophosphamide (EC) fol-
lowed either by docetaxel or docetaxel plus carboplatin. The
addition of the platinum did not improve pCR rates (35%
versus 30%) in this study. Silver et al. evaluated the efficacy
of neoadjuvant cisplatin in 28 patients with TNBC [22]. All
patients received 4 cycles of cisplatin preoperatively, followed
by definitive surgery, and then adjuvant chemotherapy and/or
radiation as per their treating physicians. The pCR rate
was 21% (6 of 28 patients), while 64% (18 of 28) achieved
either a clinical complete or partial response. The efficacy of
neoadjuvant cisplatin in TNBC versus non-TNBC was also
compared in a small retrospective study by Sirohi et al. [23].
Complete response rates by clinical exam were higher for
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those with TNBC (88%) versus the non-TNBC group (51%).
Paradoxically survival outcomes were worse for the TNBC
group despite higher rates of initial response to chemother-
apy. This has also been seen in a study which showed that,
despite a higher rate of chemosensitivity, patients with TNBC
had a worse outcome that those with ER positive disease [29].
Multiple other small studies have also evaluated neoadjuvant
platinum-based therapy in patients with TNBC with varying
results [18, 24, 25, 30–34]. While current data provides
insufficient evidence for the routine use of platinum-based
therapy in patients with TNBC, several ongoing prospective
studies will help define the role of these agents in the treat-
ment of this subset of patients. Notable among these studies
the GeparSixto study exploring the addition of carboplatin
to neoadjuvant therapy for patients with early-stage TNBC as
well asHER2-positive disease [26] demonstrated an improve-
ment in pCR rate from 37.9% to 58.7% (𝑃 < 0.05) with the
addition of carboplatin in the TNBC group but not in the
HER2+ breast cancer group (33.1% with carboplatin and
36.3% without carboplatin, n.s.) (ASCO 2013, abstract 1004).
The Cancer and Leukemia Group B (CALGB) 40603 is
evaluating the addition of carboplatin and/or bevacizumab to
standard chemotherapy in the neoadjuvant setting for TNBC
[26]. The challenge remains to identify the subpopulation
with DNA repair defects that render them particularly plat-
inum sensitive.
4. Neoadjuvant Targeted Therapy for TNBC
Different biologics such as antiangiogenic agents, poly-
ADP ribose polymerase (PARP) inhibitors, and other small
molecule inhibitors are being evaluated in patients with
TNBC. As a higher level of vascular endothelial growth
factor (VEGF) has been detected in TNBC [35], the VEGF
inhibitor, bevacizumab, has been investigated in patients
with TNBC. Two large randomized clinical trials have been
recently reported. The GeparQuinto trial was designed to
evaluate different neoadjuvant approaches in patients with
HER2-negative breast cancers, HER2-negative cancers that
did not have a response to initial neoadjuvant chemotherapy,
and HER2-positive breast cancers [36]. The primary goal of
the HER2-negative portion of this trial was to compare pCR
rates with and without bevacizumab added to chemotherapy.
All patients received EC followed by docetaxel. Patients were
randomized to receive bevacizumab or no additional therapy.
Those who did not respond to EC were then randomly
assigned to paclitaxel with or without everolimus. Among
663 patients with TNBC, the pCR rates were 27.9% in the
no bevacizumab group and 39.3% in the group that received
chemotherapy plus bevacizumab (𝑃 = 0.003). These findings
were not confirmed in the other large neoadjuvant study,
NSABP B-40 [19]. Here, although there was a numerically
higher pCR rate in the patients with TNBC that received
bevacizumab, thiswas not significant. In contrast to the previ-
ous study, patients with hormone receptor (HR) positive dis-
ease who received bevacizumab had a higher pCR rate than
thosewho did not receive it. Bevacizumab plus chemotherapy
led to an increase in toxicity in both clinical trials, most
notably hypertension. Given these differences, it is premature
to speculate that adding bevacizumab to chemotherapy will
benefit all patients with TNBC. CALBG 40603 has completed
accrual and will hopefully shed light on which subset of
TNBC, if any, will benefit from bevacizumab.
PARP enzymes mediate repair of single-strand DNA
breaks through base excision repair mechanism. Loss of
PARP enzymes will therefore lead to accumulation of single-
strand breaks which under normal circumstances ought
to be repaired by the homologous recombination pathway.
Since the homologous recombination pathway is deficient in
BRCA-associated breast cancers, PARP inhibition leads to
“synthetic lethality” in these cancers. As TNBC have clini-
copathologic similarities to BRCA associated breast cancers,
PARP inhibitors are attractive treatments for this group of
patients. Olaparib has been investigated in patients with
advanced TNBC- or BRCA-associated breast cancer with
mixed results [37–39]. Other neoadjuvant studies are ongoing
or recently reported. These include the SOLTI NEOPARP
[27], which investigates iniparib, a drug initially thought to
be a PARP inhibitor whichwas later disproven, plus paclitaxel
versus, paclitaxel alone as neoadjuvant treatment in TNBC
patients and I-SPY 2, which employs an adaptive trial design.
A subset of TNBC patients on this trial will receive paclitaxel
with or without veliparib in the neoadjuvant setting [26].
Other features of TNBC such as activation of the PI3 K/
AKT/mTOR pathway and notch signaling and overexpres-
sion of EGFR and c-KIT continue to be exploited for treat-
ment opportunities [26, 28] (Table 2).
5. Pathologic Complete Response (pCR)
Achievement of pCR is highly predictive of long-term out-
come for patients with TNBC despite the various definitions
of pCR applied in individual studies [29, 40–42], including
ypT0 ypN0 (no invasive or noninvasive residual in breast or
nodes) [43], ypT0/is ypN0 (no invasive residual in breast or
nodes, noninvasive breast residual allowed) [44–46], ypT0/is
yN0/+ (no invasive residual in the breast, noninvasive breast
residuals and infiltrated lymph nodes allowed) [2, 47], and
ypT≤1mic ypN0/+ (no gross invasive residuals in the breast,
focal invasive and noninvasive residuals in breast and
infiltrated lymph nodes allowed) [48]. However, the most
stringent definition of pCR, no invasive and in situ (DCIS)
residuals in breast and nodes, has been suggested to be most
prognostic by a recent large pooled analysis of 6,377 breast
cancer patients enrolled in seven prospective clinical trials
of neoadjuvant chemotherapy [42]. The poorer prognosis
associated with residual DCIS, in the absence of invasive
cancer in either breast or nodes, was surprising since theo-
retically most patients with DCIS are cured therefore sug-
gesting that these patients may harbor occult invasive cells
that are hard to identify or the residual DCIS following
chemotherapy is somehowbiologically different. However, an
earlier retrospective analysis of 2,302 patients who received
neoadjuvant chemotherapy at a single institution showed no
difference in 5-year or 10-year DFS between groups with
ypT0 ypN0 and ypTis pN0 [49], although the sample size
was smaller. In practice, both ypT0 ypN0 and ypT0/is ypN0
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commonly used to indicate pCR than ypT0/is yN0/+ and
ypT≤1mic ypN0/+.
TNBC is associatedwith a significantly higher rate of pCR
to standard neoadjuvant compared to ER+ HER2− disease.
The rate of pCR approximates 20% or higher for TNBC in
various studies [29, 40, 41]. While those who achieved pCR
have an excellent long-term outcome, themajority of patients
with TNBC do not achieve pCR and suffer a dramatically
worse outcome compared to those with ER+ disease [29, 41].
The recurrence rate for those who did not achieve pCR is
as high as 40–50% at 5 years for TNBC [41, 42], explaining
the paradox of worse clinical outcome in general despite the
higher likelihood of chemosensitivity. There is a significant
unmet clinical need for novel therapeutics development in
the resistant population.
In addition to pCR, quantitation of residual disease bur-
den in the breast and lymph nodes, including the use of resid-
ual cancer burden (RCB) [50] and Miller-Payne Scores [51],
could further categorize those with non-pCR into separate
prognostic groups. Although these scorings are not routinely
assessed in clinical practice, some have been incorporated
in clinical trials to identify the highest risk population for
novel therapeutics development in the adjuvant setting. One
example is the ongoing study conducted by the Hoosier
Oncology Group that assesses PARP inhibition in patients
with triple negative breast cancer or ER/PR+, HER2 negative
disease with known BRCA1/2 mutations (NCT01074970)
who had Miller-Payne response in the breast of 0–25 or RCB
classification of II or III followingneoadjuvant chemotherapy.
6. The Neoadjuvant Setting as
a Research Platform
The induction of a pCR in response to neoadjuvant chemo-
therapy effectively categorizes heterogeneous TNBC into
high- and low-risk groups. Unfortunately, there has not been
any effective therapy for those with chemotherapy-resistant
disease. There has been significant interest in analyzing
residual tumors in order to uncover molecular aberrations as
potential therapeutic targets. Balko et al. presented an anal-
ysis with targeted next-generation sequencing (NGS) of 182
oncogenes and tumor suppressors and gene expression profil-
ing of residual breast cancer after neoadjuvant chemotherapy
in 102 patients with TNBC in the recent San Antonio Breast
Cancer Symposium [52]. Eighty-nine posttreatment tumors
were evaluable for gene expression and included basal-like
(64%), HER2-enriched (19%), luminal A (6%), luminal B
(6%), and normal-like (5%) subtypes. Of 81 tumors evalu-
ated by NGS, common genetic aberrations include muta-
tions in TP53 (89%), MCL1-amplification (27%), and MYC-
amplification (21%). Common pathway alterations at the
DNA level included PI3 K/mTOR pathway (33%), cell cycle
genes (31%), DNA repair pathway (20%), and the Ras/MAPK
pathway (12%). Sporadic growth factor receptor amplifica-
tions occurred. MYC amplification was an independent poor
prognostic indicator of recurrence-free survival (RFS) and
overall survival (OS). Adjuvant trials are being designed to
address specific hypothesis originated from this investigation.
This study underscores the complexity and the diversity of
genetic abnormalities in the residual tumors that we are up
against. Effective preclinical models and novel trial designs
are needed in order to decipher the driver genetic events and
validate potentially actionable targets for TNBC.
Improvement in the rate of pCR has been considered an
accepted endpoint for neoadjuvant clinical trials in patients
with TNBC so that drugs could be tested efficiently. The abil-
ity to obtain sufficient high-quality tumormaterial before and
after therapy makes it possible to correlate biomarkers with
pathologic response. Furthermore, specific biomarkers could
be incorporated in the trial design as an eligibility criteria or
stratification factor to enhance the power to address specific
biomarker hypothesis.
To facilitate early access of potentially active drugs for
patients with high-risk disease, the Food and Drug Adminis-
tration (FDA) has recently outlined a pathway for accelerated
drug approval based on pCR from neoadjuvant trials. How-
ever, disease-free survival (DFS) and overall survival (OS)
remain the standard endpoints for eventual drug approval.
Large neoadjuvant trials that are powered for these endpoints
may be preferred. Alternatively, adjuvant trials could be
conducted while the drug receives accelerated approval so
that the DFS and OS endpoints could be assessed.
7. Controversies and Unanswered Questions
Thedata currently available on neoadjuvant chemotherapy in
primary breast cancers leaves many questions unanswered.
For instance, what is the role of further non cross-resistant
systemic therapy in TNBC patients who do not respond to
initial neoadjuvant chemotherapy? In the aforementioned
GeparTrio study [20, 53], patients who did not respond
initially to 2 cycles of TACwere randomized to further chem-
otherapy with TAC or capecitabine plus vinorelbine. pCR
rates seen in nonresponders who received further cycles of
TAC were 7.3% versus 3.1% in the capecitabine plus vinorel-
bine group supporting the hypothesis that chemotherapy-
resistant patients may not benefit from a switch to different
conventional chemotherapy agents/regimens. Similarly, the
Aberdeen trial reported a pCR rate of 2% in patients who
received neoadjuvant docetaxel after proving unresponsive to
a doxorubicin-based neoadjuvant regimen, while those who
were initially chemosensitive to the doxorubicin-containing
regimen and received further docetaxel had a pCR of 31%
[54]. Although neither study was restricted to patients with
TNBC, one can assume this to hold true in that subtype
as well. Trials are ongoing to address this specific issue in
patients with TNBC [26].
At the other end of the response spectrum questions are
beginning to be asked as to whether a subset of TNBCs who
achieve pCRdonot require the full complement of local treat-
ments (completion node dissection and/or extensive locore-
gional radiation). The consideration to withhold definitive
surgery from any patient who achieves such a clinical or radi-
ological response to neoadjuvant chemotherapy is certainly
premature at this time considering that our current tools
for assessing response to neoadjuvant chemotherapy are very
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Table 3: Benefits of performing SLNB before or after neoadjuvant
chemotherapy.
Benefits of SLNB before
neoadjuvant chemotherapy
Benefits of SLNB after
neoadjuvant chemotherapy
Allows for accurate lymph node
staging
May eliminate the need for
two surgical procedures, thus
decreasing morbidity
May impact on choice of
systemic therapy and radiation
therapy
If clinically positive lymph
nodes are down staged,
patients may avoid a full
axillary dissection
Accuracy of SLNB may be




therapy is not delayed
insensitive to microscopic but clinically relevant residual
disease. A small European study compared the accuracy of
clinical examination, mammography, ultrasonography, and
dynamic MRI in predicting response to neoadjuvant chemo-
therapy [55]. All fifteen patients underwent definitive surgery
and had their pathology results compared with clinical exam-
ination and radiologic findings during and after neoadjuvant
chemotherapy. MRI performed the best in discriminating
between the presence and absence of residual disease in 100%
of cases and was also able to evaluate the extent of residual
disease in 80%.Mammographywas able to do this in 86% and
53%, respectively. However, MRI was only able to detect mul-
tifocal/multicentric disease in 67% following neoadjuvant
chemotherapy. As the pattern of residual disease on histologic
examination following neoadjuvant chemotherapy may vary,
MRI or other imaging modalities may therefore not accu-
rately detect small volume residual disease, particularly if
located in different quadrants. Another larger study com-
pared clinical examination with ultrasonography and mam-
mography [56]. Tumor size estimation by clinical examina-
tion and then by both imaging techniques did not correlate
well with pathologic results. PET/CT scanning as a modality
to predict response to neoadjuvant therapy in TNBC was
recently reported by Groheux et al. [57]. pCR was found in 6
of 20 (30%) study patients. The area under the receiver oper-
ating characteristic curve representing the ability of pre- to
postneoadjuvant chemotherapy change in SUV in predict-
ing pathology findings of non-pCR versus pCR was 0.881.
Imaging research continues to advance as tools are refined;
the question as to which group of patients may safely omit
surgery may eventually need to be addressed.
Another key question concerns the best timing of sentinel
lymph nodal biopsy (SLNB) in patients undergoing neoad-
juvant chemotherapy. The benefits and disadvantages of per-
forming this procedure either before or after chemotherapy
are summarized in Table 3. The strongest argument in favor
of performing this before chemotherapy is that it accurately
measures the presence or absence of nodal disease for proper
staging considering that a number of patients will have their
nodal disease treated by chemotherapy. On the other hand,
SLNB done before surgery could affect the assessment of
pathologic response in lymph node. In addition, SLNB done
after preoperative chemotherapy is successful [58] and may
decrease morbidity by eliminating multiple procedures or
perhaps even a full axillary dissection. In patients with his-
tologically confirmed positive lymph nodes, the accuracy of
SLNB after neoadjuvant chemotherapy is the subject of ongo-
ing trials [26]. Theoretically when chemotherapy success-
fully clears lymph-nodes, completion dissection and regional
nodal radiation are unnecessary.
8. Conclusion
Neoadjuvant chemotherapy is now a standard of care for
a subgroup of patients with TNBC, particularly those with
clinical stage 2B or 3 disease, but it could be reasonably argued
that any patient with a biopsy that shows invasive disease
would be eligible. This approach promotes breast conserva-
tion and provides an important platform for translational
research. pCR is an appropriate surrogate for measuring
long-term clinical outcome in TNBC. Although pCR rates
to standard chemotherapy are higher in TNBC compared to
HR positive breast cancer, the large proportion of patients
with TNBC that do not achieve pCR presents a therapeutic
challenge. Further studies are therefore critical to identify
predictors of resistant population so that mechanism-based
interventions could be designed in the neoadjuvant setting to
improve pCR rates and long-term outcome. Studies are also
needed to address ongoing controversies and debates includ-
ing the use of axillary surgery and the role of postoperative
regional radiotherapy (nodes and chest wall in the setting of
mastectomy) in patients with pCR.
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